Opposition questions spending plans, with P.E.I. set to get $168M in tobacco settlement
There were questions in the P.E.I. legislature this week about how the province will spend its share of a massive settlement with the tobacco industry.
The $32.5-billion agreement among Canadian provinces and territories and the major tobacco companies — JTI-Macdonald Corp., Imperial Tobacco Canada Ltd., and Rothmans, Benson & Hedges — compensates governments for health-care costs related to smoking-related illnesses.
The legal battle dates back decades.
P.E.I. is set to receive $168 million over the next 15 to 20 years.
In the legislature on Wednesday, Liberal MLA Robert Henderson asked Justice and Public Safety Minister Bloyce Thompson for details on how the money will be allocated.
"In the recent budget tabled in this legislature under revenue from provincial sources, P.E.I. is receiving a $36.4-million windfall from tobacco litigation," Henderson said.
"This money seems to be going to general revenue, but I can't find any budget lines that say how that money goes to families of smokers who have health-related deaths from tobacco. How do families claim that money?"
In response, Thompson said: "The money is designated for the health-care system to help deal with the situations from smoking over the years. It will be a great help to our health-care system and there is a way that individuals can apply for some money.
"I would be happy to table the procedure on how individuals can apply for that here today or tomorrow."
Smokers, former smokers or their representatives living in Canada will be able to seek individual compensation through Tobacco Claims Canada, but the claims process hasn't begun yet.
That's a separate process from the funding going to the P.E.I. government.
Fund to help improve smoking cessation program
Henderson also questioned Minister of Health and Wellness Mark McLane about whether any of the settlement funds will go toward groups that have been pushing for smoking reduction efforts.
"The Cancer Society and the P.E.I. Tobacco-Free Spaces have been advocating for increased funding for enhanced smoke reduction programming. Yet I see in the Department of Health and Wellness budget under health promotion, grants have been reduced over last year's allotment," Henderson said.
"Will these groups receive any funding from the tobacco settlement dollars to P.E.I.?"
McLane responded that the province is using the extra funding for preventative measures, including improvements to the smoking cessation program available through Island pharmacies.
Henderson also questioned the province on why the $36.4 million went into general revenue without a specific budget line to compensate families affected by smoking-related health issues.
In response, McLane said: "It does go into general revenues, like every other province in Canada, to continue to improve smoking cessation programs, and we talked about the lung screening program, that those investments will go towards in the future."
Elsewhere in the Maritimes, New Brunswick is set to receive about $614 million from the settlement, while Nova Scotia's share is roughly $809 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
11 hours ago
- Winnipeg Free Press
Digging for the truth
For eight hours after home-care nurse Heather O'Brien was shot in the head by Nova Scotia mass murderer Gabriel Wortman, her Fitbit continued to send a signal to her home computer showing heart activity. The RCMP officer at the scene felt her pulse, then covered her with a sheet and treated her as dead. Senior Mounties had ruled out sending an ambulance, fearing the paramedics would become targets. O'Brien's family knew she would not have lived, even if she had received treatment. But they wanted the screenshot of her heart activity included in the evidence of the Mass Casualty Commission (MCC), established by the province ostensibly to find the truth and give a voice to the families of the 22 victims of the 2020 shootings. Andrew Vaughan / The Canadian Press files In this April 2020 photo, the medical examiner's office team remove Gabriel Wortman's body from a gas bar in Enfield, N.S. after he was shot dead by police. The commission refused to include the evidence, so the family released the screenshot and their statements on Facebook to let the public know the commission was not providing the full story. Author Paul Palango calls the O'Brien family's experience a perfect example of how the MCC 'favoured the RCMP's official narrative despite contradictory evidence.' The veteran Canadian journalist disassembles that narrative on every page of this exposé, from its confrontational title to its final words: 'The story as told by the RCMP, the Mass Casualty Commission and politicians is full of holes.' Palango won awards for investigative journalism during his tenure as national editor at the Globe and Mail. He is the author of four books about the RCMP, including 22 Murders, also about Wortman's killings, from which he quotes frequently and extensively. If the Mounties had simply admitted they had been caught off-guard, short-handed and ill-prepared by Wortman's murderous rampage on April 18 and 19, 2020, most Canadians would have forgiven them. Instead, Palango documents how institutional rot in the RCMP caused the Mounties to make crucial errors in responding to the gunman, who was wearing an RCMP uniform and driving what looked like an RCMP car. Then, instead of coming clean, Palango says Mounties destroyed and suppressed evidence and lied about what really happened to cover up their own incompetence. They were aided and abetted by the MCC, the author says, which adopted procedural rules that made it almost impossible to get to the truth. Was Gabriel Wortman, a Dartmouth denturist by day, a paid police informant? RCMP handout / Canadian Press files Gabriel Wortman After digging through old search warrants and interviewing those closest to Wortman, Palango speculates that Wortman smuggled drugs and weapons across the U.S. border and sold them to the Hells Angels, along with pill presses for the drugs, something denturists have. These ones were bugged, giving the RCMP a direct line on gang activities. After one too many police raids followed the same pattern, the Hells Angels were likely thinking Wortman was a 'rat' and planning to kill him, Palango speculates. That would explain Wortman's sudden urge to get out of town. He was selling his real estate and dissolving his business. Wortman collected $475,000 in cash from Brink's a mere 18 days before he started killing people. Was the money Wortman received a payout from the police? No, the commission replied, there was 'no evidence' he was a paid informant. But the same document concedes that even if he had been, no one would admit it, even after his death. Palango believes key facts about other aspects of the official narrative were altered or suppressed, including how Wortman was killed, his girlfriend Lisa Banfield's alibi and how two Mounties shot at and almost killed another Mountie, thinking he was Wortman. Accepting the book's premises requires the reader to take Palango's side against all of officialdom. But his over-sized ego keeps getting in the way. Anatomy of a Cover-Up He repeatedly interrupts the narrative to crow about what an outstanding journalist he is, and more importantly, how dull and slow-witted all the other journalists are. When he finally makes a mistake — and it's a doozy — he owns up to it and apologizes to his print and podcast audiences. But in the next breath, he absolves himself: 'Another positive was that our wrong assumption didn't get anyone killed.' Cringe. For readers who can get over tone-deaf passages along those lines, Palango delivers a mother lode of facts and well-informed speculation about the biggest mass shooting in Canadian history. Palango concedes that he can't be absolutely sure he has all the right answers, but he has done a great service to the victims' families and all Canadians by tirelessly asking the right questions. Donald Benham is a freelance writer living near Beausejour.
The Market Online
a day ago
- The Market Online
U.S. federal cannabis rescheduling: A game-changer for Canopy Growth?
The U.S. government is considering reclassifying cannabis from Schedule I to Schedule III, which would recognize its medical benefits, ease research restrictions, and offer tax relief to cannabis businesses Through its Canopy USA structure, Canopy Growth holds stakes in major U.S. cannabis companies like Acreage Holdings, Wana Brands, and Jetty, positioning itself to capitalize on federal policy changes Canopy Growth reported a 43 per cent year-over-year increase in Canadian adult-use cannabis revenue in Q1 FY2026, signaling operational momentum as it prepares for potential U.S. market expansion Canopy Growth stock (TSX:WEED) last traded at C$2.08 The United States could be on the cusp of a transformative shift in federal cannabis policy. Recent statements from President Donald Trump and widespread media coverage confirm that the administration is currently reviewing a proposal to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This content has been prepared as part of a partnership with Canopy Growth Corp. and is intended for informational purposes only. This reclassification would mark the most significant federal policy change in over 50 years, formally acknowledging cannabis's medical utility and opening new avenues for research, patient access, and industry growth. Currently, cannabis is classified alongside heroin and LSD under Schedule I, a category reserved for substances with no accepted medical use and high abuse potential. Moving it to Schedule III—alongside drugs like ketamine and anabolic steroids—would signal a federal recognition of its therapeutic potential and reduce regulatory burdens. Implications of Schedule III reclassification If cannabis is reclassified, the following changes are expected: Medical recognition : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. Expanded research : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. Tax relief: Cannabis businesses would no longer be subject to Section 280E of the IRS tax code, which currently prevents them from deducting ordinary business expenses. This could significantly improve profitability across the sector. Regulatory clarity: While not full legalization, Schedule III status would provide a more stable regulatory environment, encouraging institutional investment and broader market participation. With the U.S. retail cannabis market projected to reach approximately US$50 billion by 2026, the stakes are … high. Canopy Growth: Positioned for U.S. expansion Canopy Growth Corp. (TSX:WEED, NASDAQ:CGC) has positioned itself to capitalize on the evolving U.S. cannabis landscape through its Canopy USA structure. This unconsolidated, non-controlling entity holds a portfolio of U.S. cannabis assets, including: Acreage Holdings, Inc. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. Wana Brands – An edibles company. – An edibles company. Jetty (Lemurian, Inc.) – A California-based producer of premium cannabis extracts and vape technology. – A California-based producer of premium cannabis extracts and vape technology. The Cima Group and Wana Wellness – Expanding Canopy's reach into wellness and lifestyle segments. This structure allows Canopy to maintain compliance with U.S. federal regulations while retaining exposure to the upside of U.S. market growth. Shareholders recently approved the creation of a new class of exchangeable shares; a move designed to accelerate Canopy's U.S. market entry and enhance flexibility. Financial momentum and solid readiness Canopy Growth's Q1 FY2026 results reflect a company regaining momentum: Canada adult-use cannabis net revenue rose 43 per cent year-over-year to C$27 million , driven by strong demand for new products like Claybourne infused pre-rolls. rose to , driven by strong demand for new products like Claybourne infused pre-rolls. Total cannabis revenue increased 24% , while consolidated net revenue grew 9 per cent to C$72.1 million . increased , while consolidated net revenue grew to . The company achieved CA$17 million of its CA$20 million annualized cost savings target and reduced SG&A expenses by 21 per cent. CEO Luc Mongeau emphasized the company's focus on high-demand product categories and retail distribution, while interim CFO Tom Stewart highlighted ongoing efforts to improve gross margins and operational efficiency, stating, 'Our financial discipline has already delivered meaningful operating expense reductions, and we see further opportunity to simplify and focus the business. Improving gross margin remains a key priority while maintaining topline performance in all areas of the business.' Investor takeaway: A catalyst for revaluation The potential rescheduling of cannabis to Schedule III could be a major catalyst for Canopy Growth and the broader cannabis sector. For Canopy, it would: Unlock tax savings and improve cash flow. Enable deeper integration of its U.S. assets under Canopy USA. Attract institutional investors previously deterred by regulatory uncertainty. Accelerate revenue growth in the world's largest cannabis market. While regulatory timelines remain uncertain, the momentum is clearly building. For investors, Canopy Growth represents a well positioned, financially disciplined player ready to seize the opportunities of a rescheduled U.S. cannabis market. About Canopy Growth Canopy Growth Corp. delivers products with a focus on premium and mainstream cannabis brands, in addition to vaporizer technology made in Germany. Canopy Growth stock (TSX:WEED) last traded around 8 per cent lower at C$2.08 on the TSX. Though it has risen 10 per cent since June, it has lost 47 per cent since the year began and 78 per cent since this time last year. On the NASDAQ, CGC stock also finished 8 per cent lower at US$1.50. It has risen more than 12 per cent since June but has lost 45 per cent since the year began and is 78 per cent lower since this time last year. Join the discussion: Find out what the Bullboards are saying about Canopy Growth and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
Cision Canada
2 days ago
- Cision Canada
Prescientx Ushers in Canada's New Era of Engineered Infection Prevention
WATERLOO, ON, /CNW/ - As Canadian healthcare facilities face rising disease transmission and new national infection control standards, IPC Technologies Inc. (operating as Prescientx) announces exclusive Canadian healthcare distribution rights for a suite of advanced Engineered Infection Prevention (EIP) technologies. Prescientx is uniquely positioned to help hospitals and healthcare construction partners meet and exceed the new CSA Z8000 and Z317.12 standards—critical for compliance and Ministry of Health funding across several provinces. The new standards address critical vulnerabilities in healthcare: the need for continuous upper air disinfection, continuous surface disinfection, continuous sink disinfection and automatic whole room disinfection. Prescientx's technologies can achieve up to a 100-fold reduction in exposure to pathogens, continuously and automatically, representing a monumental leap in patient and staff safety designed to significantly reduce Healthcare Acquired Infections (HAIs). "The conversation around infection control in Canada has fundamentally changed," said Keith Hunt, President of Prescientx. "It's no longer just about daily disinfection; it's about engineering for continuous protection. The new CSA standards require a level of verifiable, engineered performance – pathogen reduction that provides a cost-benefit that daily disinfection simply cannot provide. Most importantly, they mandate EIP-qualified personnel to advise and oversee these systems. Our entire business is structured to meet this exact moment." Prescientx's exclusive portfolio includes: ASEPT-1X MAX ™ by Sanuvox – A Health Canada PMRA approved engineered patented UVC system for creating fully automated, self-disinfecting rooms in Canada. SmartFLO3 ™ by Franke – A splashless CSA-compliant self-cleaning and disinfecting, biofilm-free sink system, engineered for compatibility with UV disinfection. Sanilume by iLLUMiSoft Lighting – A Health Canada PMRA approved optimized, high-output Upper Air GUV solution, providing continuous air disinfection designed to reduce exposure to airborne pathogens to near zero levels. EOScu surfaces & Aereus copper coatings – self-disinfecting surfaces like overbed tables, countertops, bedrails, fixtures and hardware that rapidly and continually reduce pathogens on epidemiologically important, high touch surfaces. This announcement solidifies the company's strategic business model, which shed its former manufacturing arm to focus exclusively on the professional services and specialized distribution required by today's market. "Our identity has always been rooted in providing automated solutions to reduce Healthcare Acquired Infections through engineering expertise," Hunt added. "Our focused model allows us to be true, unbiased partners to IPAC Professionals, Hospital Contractors, and Facility Managers. We de-risk their projects by ensuring the solutions are not only compliant from day one but are also integrated correctly for long-term reliability and provide a stunning return on investment. We have shown payback periods as short as 23 days." Prescientx urges healthcare stakeholders to assess their readiness for the new CSA standards and explore engineered solutions that deliver continuous protection and measurable outcomes. About Prescientx Inc. Canada.
